Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microRNA-181a mimics are synthetic, double-stranded RNA oligonucleotides designed to emulate the biological activity of endogenous microRNA-181a (miR-181a). These molecules are used to restore or overexpress miR-181a levels in cellular models, where they function by binding to the 3' untranslated regions (UTRs) of specific target mRNAs, leading to translational repression or mRNA degradation. miR-181a is a member of the miR-181 family and plays a significant role in regulating hematopoiesis, immune cell development, and oncogenic processes. In multiple myeloma research, miR-181a mimics have been shown to promote cell proliferation, suggesting that miR-181a may act as an oncomiR in this specific malignancy. These mimics are primarily utilized as research-use-only (RUO) reagents to investigate the functional role of miR-181a in various diseases and to explore its potential as a therapeutic target or biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on microRNA-181a mimics.